Titanium Media App July 19 news, Johnson & Johnson (JNJ.US) Chief Financial Officer Joseph Wolk said on Tuesday that the company lowered its 2022 performance guidance while reporting better-than-expected second-quarter results because of a stronger dollar and adverse exchange rate effects. the healthcare giant's performance. It is reported that the financial report shows that Johnson & Johnson’s Q2 revenue was US$24.020 billion, exceeding market expectations by US$180 million, a year-on-year increase of 3%; Non-GAAP diluted earnings per share was US$2.59, a year-on-year increase of 4.4%, exceeding market expectations by US$0.04 . Johnson & Johnson expects 2022 sales (excluding COVID-19 vaccine revenue) to be $93.3 billion to $94.3 billion, compared with the previous forecast of $94.8 billion to $95.8 billion, and the consensus estimate of $96.09 billion; adjusted earnings per share of $10-10.1, previously Expectation is $10.15-10.35, and the consensus is $10.19.
media coverage
Titanium Media
This article is reprinted from: https://readhub.cn/topic/8hMy6NRrjgN
This site is for inclusion only, and the copyright belongs to the original author.